Human PEDF Recombinant Protein Lyophilized from Innovative Research has been recombinantly produced in E. coli. This is a Lyophilized protein buffered in with a purity of Greater than 90% by SDS-PAGE gel and HPLC analyses.

Endotoxin level is less than 0.1 ng per and#956;g (1EU/and#956;g)..

More Details:

• Species: Human
• Target: SERPINF1
• Purity: Greater than 90% by SDS-PAGE gel and HPLC analyses.
  
  Endotoxin level is less than 0.1 ng per and#956;g (1EU/and#956;g).
• Source: E. coli
• Storage Conditions: The lyophilized PEDF recombinant protein is stable for at least 2 years from date of receipt at -20°C. Reconstituted PEDF is stable for at least 3 months when stored in working aliquots with a carrier protein at -20°C. As with any protein, exposing PEDF recombinant protein to repeated freeze / thaw cycles is not recommended. When working with proteins care should be taken to keep recombinant protein at a cool and stable temperature.

Additional Information:

PEDF is a noninhibitory serpin with neurotrophic, anti-angiogenic, and anti-tumorigenic properties. It is a 50 kDa glycoprotein produced and secreted in many tissues throughout the body. A major component of the anti-angiogenic action of PEDF is the induction of apoptosis in proliferating endothelial cells. In addition, PEDF is able to inhibit the activity of angiogenic factors such as VEGF and FGF-2. The neuroprotective effects of PEDF are achieved through suppression of neuronal apoptosis induced by peroxide, glutamate, or other neurotoxins. The recent identification of a lipase-linked cell membrane receptor for PEDF (PEDF-R) that binds to PEDF with high affinity (1) should facilitate further elucidation of the underlying mechanisms of this pluripotent serpin. To date, PEDF-R is the only signaling receptor known to be used by a serpin family member. The unique range of PEDF activities implicate it as a potential therapeutic agent for the treatment of vasculature related neurodegenerative diseases such as age-related macular degeneration (AMD) and proliferative diabetic retinopathy (PDR). PEDF also has the potential to be useful in the treatment of various angiogenesis-related diseases including a number of cancers. Recombinant PEDF is a 44.5 kDa non-glycosylated protein containing 400 amino acid residues. (1) Notari, I. et al. J Biol Chem., Vol. 281, 38022-38037.

. At Innovative Research we provide reliable, consistent products that deliver reliable, consistent results.

View all citations and product references

This material is sold for in-vitro use only for manufacturing and research. This material is not suitable for human or animal use. While we make every effort to ensure the safety of our products, we recommend handling any biological materials with standard precautions as if capable of spreading infectious disease. The statements herin are offered for informational purposes only to be used solely for your consideration, investigation, and verification.

Please be aware the image pictured is for illustrative purposes only, and your product packaging and appearance may vary.

No Data Sheets available